‘Cancer Prevention Must Move From Thought to Reality’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 2
Volume 11
Issue 2

WASHINGTON-"Cancer prevention now requires that we move from thought to reality," said Carolyn Aldigé, founder and president of the Cancer Research Foundation of America (CRFA). "This mean a new paradigm of the health care system, rather than just taking care of sick people. Treatment of advanced disease has less impact than prevention."

WASHINGTON—"Cancer prevention now requires that we move from thought to reality," said Carolyn Aldigé, founder and president of the Cancer Research Foundation of America (CRFA). "This mean a new paradigm of the health care system, rather than just taking care of sick people. Treatment of advanced disease has less impact than prevention."

The Foundation has sponsored the Cancer Prevention Working Group, which has spent 2 years framing the issues and outlining challenges, she said at a meeting of the Working Group. "Now we need to formulate an action plan to take concrete steps. We must engage regulators and the primary care community and convince them that prevention is important," she said.

Ms. Aldigé said that such a plan could be devised within a year, taking the best current practices and research and weaving them into a broad cancer prevention approach.

She called for a summit meeting in the interim to deal with specific issues and barriers, especially questions of approval, regulation, and liability. The keys, she said, are further research to identify chemopreventive agents and devising ways to provide incentives to the pharmaceutical industry.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content